Skip to search formSkip to main contentSkip to account menu

PLX4032

Known as: B-Raf inhibitor PLX4032, PLX 4032, PLX-4032 
National Institutes of Health

Related topics

Related topics

2 relations
RG7204

Broader (1)

Vemurafenib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance
Tumor angiogenesis is essential for tumor growth and metastasis and is dependent on key angiogenic factors. Angiogenin (ANG), a… 
Highly Cited
2013
Highly Cited
2013
CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
Resistance to BRAF inhibitor therapy places priority on developing BRAF inhibitor-based combinations that will overcome de novo… 
Highly Cited
2011
Highly Cited
2011
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.
Highly Cited
2010
Highly Cited
2010
PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.
3534 Background: The BRAF activating mutation is present in up to 10% of metastatic colorectal carcinomas (mCRC) and is… 
Review
2010
Review
2010
Colorectal cancer molecular biology moves into clinical practice
The promise of personalised medicine is now a clinical reality, with colorectal cancer genetics at the forefront of this next… 
Highly Cited
2010
Highly Cited
2010
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
Blocking oncogenic signaling induced by the BRAFV600E mutation is a promising approach for melanoma treatment. We tested the anti… 
Highly Cited
2010
Highly Cited
2010
PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas
Targeted intervention of the B‐Raf V600E gene product that is prominent in melanoma has been met with modest success. Here, we… 
Review
2010
Review
2010
PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
PLX-4032 is a small-molecule, orally available B-Raf kinase inhibitor being developed by Plexxikon Inc and Hoffman-La Roche Ltd… 
Highly Cited
2010
Highly Cited
2010
Evaluation of commercial ResPlex II v2.0, MultiCode®-PLx, and xTAG® respiratory viral panels for the diagnosis of respiratory viral infections in adults
Highly Cited
2008
Highly Cited
2008
BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells
BRAF-activating mutations have been reported in several types of cancer, including melanoma (∼70% of cases), thyroid (30-70… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)